Improved in vitro stability of serum osteocalcin by using a new commercially available antiproteolytic compound.
The effect of a commercially available antiproteolytic compound (OSCAstabil) on the degradation in vitro of serum osteocalcin (Oc) was investigated in serum samples stored at 22, 4 or -30 degrees C (n = 20) or subjected to repeated freeze-thaw cycles (n = 8). The addition of the stabilizing agent immediately after serum preparation increased the Oc stability from < 3 to 6 h at 22 degrees C, from < 3 h to 3 days at 4 degrees C and from 1 day to more than 3 days at -30 degrees C. Up to three freeze-thaw cycles had no influence on the Oc stability, either with or without the stabilizer. The obviously prolonged Oc stability at 22 and 4 degrees C offers a more convenient and reliable Oc estimation procedure for clinical practice. The use of this antiproteolytic agent can be recommended in order to retard the in vitro degradation of serum Oc, not only for clinical routine, but also for studies on metabolic bone diseases.
Baumgrass
R
R
German Institute of Human Nutrition, Bergholz-Rehbruecke. baumgrass@enzyme-halle.mpg.de
Daenzer
M
M
Felsenberg
D
D
D000328:Adult; D005260:Female; D005615:Freezing; D006801:Humans; D006868:Hydrolysis; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D015203:Reproducibility of Results; D013048:Specimen Handling
D015675:Osteocalcin